Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada
Introduction Raltegravir is a potent HIV-integrase strand transfer inhibitor (INSTI). Despite its strong activity against HIV-1 strains resistant to other antiretroviral drug classes, it is usually used in combination with other antiretroviral drugs due to the empirical requirement for anti-HIV drug...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/7/e094384.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850090593211908096 |
|---|---|
| author | Salmaan Kanji Nancy Tremblay D William Cameron Bashour Yazji Luana Leticia Teixeira Nunes Porto Mary-Anne Doyle Guijin Zhang |
| author_facet | Salmaan Kanji Nancy Tremblay D William Cameron Bashour Yazji Luana Leticia Teixeira Nunes Porto Mary-Anne Doyle Guijin Zhang |
| author_sort | Salmaan Kanji |
| collection | DOAJ |
| description | Introduction Raltegravir is a potent HIV-integrase strand transfer inhibitor (INSTI). Despite its strong activity against HIV-1 strains resistant to other antiretroviral drug classes, it is usually used in combination with other antiretroviral drugs due to the empirical requirement for anti-HIV drug combinations to ensure effective anti-retroviral therapy (ART). As an early-arriving INSTI, raltegravir is clinically familiar for its safety, tolerability and treatment effectiveness. High-dose calcium carbonate formulated as an antacid (as opposed to a supplement formulation) taken orally together with raltegravir is known to reduce systemic raltegravir exposure due to chelation and reduced absorption. This study aims to assess the effect of daily calcium carbonate antacid as TUMS Ultra Strength (US) administration in lower doses, as currently used for oral calcium supplementation, on the steady-state pharmacokinetics (PKs) of once-daily oral raltegravir.Methods and analysis This is an open-label, three-treatment series in three periods in a single group, fixed-sequence PK study in 12 healthy adult volunteers with HIV on ART. Subjects will take 1200 mg of raltegravir single QD oral dose alone for 7 days (period one), then raltegravir 1200 mg with calcium carbonate 500 mg from day 8 to day 14 (period two) and raltegravir 1200 mg with calcium carbonate 1000 mg from day 15 to day 22 (period three). We will conduct serial PK sampling from observed dosing on days 7, 14 and 21, with 24-hour PK sampling scheduled for days 8, 15 and 22. Follow-up will continue until day 51.Ethics and dissemination This study will adhere to the ICH GCP Guidelines and the Declaration of Helsinki. Ethics approval was obtained from the Ottawa Health Science Network Research Ethics Board under study ID 20190750–01 hour. Informed consent will be obtained from all participants prior to enrolment. This protocol will be published in a peer-reviewed journal prior to the study’s completion and closure. Results generated from this activity will also be reported in a peer-reviewed journal.Trial registration number NCT04258475. |
| format | Article |
| id | doaj-art-87d0372f3fbb44259216cd010b2a1267 |
| institution | DOAJ |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-87d0372f3fbb44259216cd010b2a12672025-08-20T02:42:32ZengBMJ Publishing GroupBMJ Open2044-60552025-07-0115710.1136/bmjopen-2024-094384Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in CanadaSalmaan Kanji0Nancy Tremblay1D William Cameron2Bashour Yazji3Luana Leticia Teixeira Nunes Porto4Mary-Anne Doyle5Guijin Zhang6Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaOttawa Hospital Research Institute, Ottawa, Ontario, CanadaClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaOttawa Hospital Research Institute, Ottawa, Ontario, CanadaClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, CanadaOttawa Hospital Research Institute, Ottawa, Ontario, CanadaOttawa Hospital Research Institute, Ottawa, Ontario, CanadaIntroduction Raltegravir is a potent HIV-integrase strand transfer inhibitor (INSTI). Despite its strong activity against HIV-1 strains resistant to other antiretroviral drug classes, it is usually used in combination with other antiretroviral drugs due to the empirical requirement for anti-HIV drug combinations to ensure effective anti-retroviral therapy (ART). As an early-arriving INSTI, raltegravir is clinically familiar for its safety, tolerability and treatment effectiveness. High-dose calcium carbonate formulated as an antacid (as opposed to a supplement formulation) taken orally together with raltegravir is known to reduce systemic raltegravir exposure due to chelation and reduced absorption. This study aims to assess the effect of daily calcium carbonate antacid as TUMS Ultra Strength (US) administration in lower doses, as currently used for oral calcium supplementation, on the steady-state pharmacokinetics (PKs) of once-daily oral raltegravir.Methods and analysis This is an open-label, three-treatment series in three periods in a single group, fixed-sequence PK study in 12 healthy adult volunteers with HIV on ART. Subjects will take 1200 mg of raltegravir single QD oral dose alone for 7 days (period one), then raltegravir 1200 mg with calcium carbonate 500 mg from day 8 to day 14 (period two) and raltegravir 1200 mg with calcium carbonate 1000 mg from day 15 to day 22 (period three). We will conduct serial PK sampling from observed dosing on days 7, 14 and 21, with 24-hour PK sampling scheduled for days 8, 15 and 22. Follow-up will continue until day 51.Ethics and dissemination This study will adhere to the ICH GCP Guidelines and the Declaration of Helsinki. Ethics approval was obtained from the Ottawa Health Science Network Research Ethics Board under study ID 20190750–01 hour. Informed consent will be obtained from all participants prior to enrolment. This protocol will be published in a peer-reviewed journal prior to the study’s completion and closure. Results generated from this activity will also be reported in a peer-reviewed journal.Trial registration number NCT04258475.https://bmjopen.bmj.com/content/15/7/e094384.full |
| spellingShingle | Salmaan Kanji Nancy Tremblay D William Cameron Bashour Yazji Luana Leticia Teixeira Nunes Porto Mary-Anne Doyle Guijin Zhang Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada BMJ Open |
| title | Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada |
| title_full | Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada |
| title_fullStr | Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada |
| title_full_unstemmed | Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada |
| title_short | Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada |
| title_sort | influence of concurrent oral calcium carbonate supplementation on steady state pharmacokinetics of once daily oral raltegravir in persons with hiv a protocol for a prospective open label non randomised study in canada |
| url | https://bmjopen.bmj.com/content/15/7/e094384.full |
| work_keys_str_mv | AT salmaankanji influenceofconcurrentoralcalciumcarbonatesupplementationonsteadystatepharmacokineticsofoncedailyoralraltegravirinpersonswithhivaprotocolforaprospectiveopenlabelnonrandomisedstudyincanada AT nancytremblay influenceofconcurrentoralcalciumcarbonatesupplementationonsteadystatepharmacokineticsofoncedailyoralraltegravirinpersonswithhivaprotocolforaprospectiveopenlabelnonrandomisedstudyincanada AT dwilliamcameron influenceofconcurrentoralcalciumcarbonatesupplementationonsteadystatepharmacokineticsofoncedailyoralraltegravirinpersonswithhivaprotocolforaprospectiveopenlabelnonrandomisedstudyincanada AT bashouryazji influenceofconcurrentoralcalciumcarbonatesupplementationonsteadystatepharmacokineticsofoncedailyoralraltegravirinpersonswithhivaprotocolforaprospectiveopenlabelnonrandomisedstudyincanada AT luanaleticiateixeiranunesporto influenceofconcurrentoralcalciumcarbonatesupplementationonsteadystatepharmacokineticsofoncedailyoralraltegravirinpersonswithhivaprotocolforaprospectiveopenlabelnonrandomisedstudyincanada AT maryannedoyle influenceofconcurrentoralcalciumcarbonatesupplementationonsteadystatepharmacokineticsofoncedailyoralraltegravirinpersonswithhivaprotocolforaprospectiveopenlabelnonrandomisedstudyincanada AT guijinzhang influenceofconcurrentoralcalciumcarbonatesupplementationonsteadystatepharmacokineticsofoncedailyoralraltegravirinpersonswithhivaprotocolforaprospectiveopenlabelnonrandomisedstudyincanada |